Back to today’s briefing

Story perspectives

FDA Grants Rare Disease Designation to Ocugen's Gene Therapy

5/30/2025

50 4

Summary

Ocugen Advances Gene Therapy

Ocugen has achieved a significant milestone with the FDA granting Rare Pediatric Disease Designation for its innovative gene therapy, OCU410ST, aimed at treating ABCA4-associated retinopathies like Stargardt disease. With plans to launch a Phase 2/3 trial soon, the company is on track to submit a Biologics License Application by 2027, bringing hope to patients in need.

Summary

HHS Cancels Moderna Contract

The U.S. Department of Health and Human Services has scrapped a $600 million contract with Moderna aimed at flu vaccine development, while the FDA has turned down a drug for Barth syndrome, impacting around 150 patients. These setbacks underscore the persistent hurdles faced by the pharmaceutical industry in securing funding and navigating regulatory landscapes.

1 of 2

Ocugen Advances Gene Therapy

Ocugen has achieved a significant milestone with the FDA granting Rare Pediatric Disease Designation for its innovative gene therapy, OCU410ST, aimed at treating ABCA4-associated retinopathies like Stargardt disease. With plans to launch a Phase 2/3 trial soon, the company is on track to submit a Biologics License Application by 2027, bringing hope to patients in need.

1 / 2